• Merih Ozgen, Didem Turgut Cosan, Fulya Doganer, Ahu Soyocak, Onur Armagan, Hasan Veysi Gunes, Irfan Degirmenci, Gulsah Ogutler Ozkara, and Fezan Sahin Mutlu.
• Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Eskişehir Osmangazi University, Eskisehir, Turkey.
• Clinics (Sao Paulo). 2012 Nov 1; 67 (11): 129913021299-302.

ObjectiveThe development of osteoporosis is associated with several risk factors, such as genetic structures that affect bone turnover and bone mass. The impact of genetic structures on osteoporosis is not known. Plasminogen activator inhibitor type-1 regulates the bone matrix and bone balance. This study assessed the correlation between plasminogen activator inhibitor type-1 gene 4G/5G polymorphisms and osteoporosis in a population of Turkish women.MethodsA total of 195 postmenopausal female patients who were diagnosed with osteoporosis (Group I) based on bone mineral density measurements via dual-energy x-ray absorptiometry and 90 females with no osteoporosis (Group II) were included in this study. Correlations between PAI-1 gene 4G/5G polymorphisms and osteoporosis were investigated through the identification of PAI-1 gene 4G/5G polymorphism genotypes using the polymerase chain reaction.ResultsNo significant differences in the genotype and allele frequency of 4G/5G plasminogen activator inhibitor type-1 polymorphisms were observed between the two groups, and both groups exhibited the most frequently observed 4G5G genotype.ConclusionNo correlation between the development of osteoporosis in the female Turkish population and 4G/5G plasminogen activator inhibitor type-1 gene polymorphisms was observed.

23 keywords...

hide…